United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

al ittihad drug store france - 200 ml vial - infusion - 10 g/ 200ml - immunologicals , vaccines-immunoglobulins

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alphamed drug store jordan - 200 ml bag - infusion - 400 mg/200 ml - infections-antibacterial

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

shandong rainbow international co ltd - pyraclostrobin - unknown - pyraclostrobin carbamate-methoxy active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - pyraclostrobin - unknown - pyraclostrobin carbamate-methoxy active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rudong zhongyi chemical co. ltd - pyraclostrobin - unknown - pyraclostrobin carbamate-methoxy active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

colin campbell (chemicals) pty ltd - pyraclostrobin - unknown - pyraclostrobin carbamate-methoxy active 0.0 - fungicide

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 200mg;  ;   - tablet - 200 mg - active: carbamazepine 200mg     excipient: carmellose sodium colloidal silicon dioxide magnesium stearate microcrystalline cellulose - · epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 200mg;  ;   - modified release tablet - 200 mg - active: carbamazepine 200mg     excipient: carmellose sodium colloidal silicon dioxide ethylcellulose hypromellose yellow, red, white suspension iron oxide red iron oxide yellow magnesium stearate methacrylic acid copolymer microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified talc   purified water titanium dioxide - epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; indigo carmine; lactose monohydrate; erythrosine; sodium lauryl sulfate; titanium dioxide; maize starch; gelatin; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; industrial methylated spirit; dimeticone 1510; lecithin - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extens

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated) (unii: 5i5hvc73i8) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) - unii:euj84un96z) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. do not administer influenza a (h1n1) 2009 monovalent vaccine to anyone with a known severe hypersensitivity to egg proteins or any component of the vaccine or life-threatening reactions after previous administration of any influenza vaccine. [see warnings and precautions (5) and description (11) ] sanofi pasteur's influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluzone vaccine) are manufactured by the same process. available information for fluzone vaccine is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluzone vaccine. it is also not known whether these vaccines can cause fetal harm when administered to a pregnant woman or can affect reproduction